CredoScientia - Bibliothèque

An autoethnographic critique of a past report of inpatient psychiatric treatment for gender diverse children.

OBJECTIVE: To review reporting on a case series of "inpatient therapy" administered to pre-pubertal children presenting with gender expansive behaviours previously published in the MJA and to compare …

Thérapies de Conversion

McFadyen, J., Jones, T. W., Koek, R., Harte, F., Jansen, B., Galbally, M., Kealy-Bateman, W., Wall, C., McLamore, Q., & Ravine, A. (2025). An autoethnographic critique of a past report of inpatient psychiatric treatment for gender diverse children.. Med J Aust, 223(7), 359-364. https://doi.org/10.5694/mja2.70037

06/10/2025 Lire →

Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study.

BACKGROUND: The optimal conversion regimen that allows more patients with unresectable biliary tract cancer to access surgery remains unclear; there is currently no standard conversion therapy for bil…

Thérapies de Conversion

Shi, G., Huang, X., Li, X., Liang, F., Gao, Q., Zhang, D., Lu, J., Ji, Y., Hu, Z., Chen, Y., Qiu, S., Yi, Y., Zhu, X., Sun, H., Shi, Y., Peng, M., Wang, X., Huang, C., Ding, Z., … Fan, J. (2025). Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study.. Lancet Oncol, 26(10), 1334-1345. https://doi.org/10.1016/S1470-2045(25)00376-6

01/10/2025 Lire →

Conversion Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Retrospective Cohort Study.

BACKGROUND AND OBJECTIVES: Intrahepatic cholangiocarcinoma (iCCA) is a highly malignant biliary tumor associated with a poor prognosis. Here, we explored conversion therapy (CT) for the treatment of l…

Thérapies de Conversion

Lu, J., Zhou, L., Zhang, S., Li, J., Liu, T., & Huang, B. (2025). Conversion Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Retrospective Cohort Study.. J Surg Oncol, 132(5), 917-923. https://doi.org/10.1002/jso.70068

01/10/2025 Lire →

[The research progress of neoadjuvant and conversion therapy in biliary tract carcinoma].

Biliary tract carcinoma (BTC) is a highly aggressive malignancy,and the majority of patients present with advanced stage at first diagnosis which resulting in poor prognosis. Traditional chemotherapy …

Thérapies de Conversion

Lan, C. L., Zeng, Z. M., Zhu, G. Z., & Peng, T. (2025). [The research progress of neoadjuvant and conversion therapy in biliary tract carcinoma].. Zhonghua Wai Ke Za Zhi, 63(10), 904-910. https://doi.org/10.3760/cma.j.cn112139-20250110-00015

01/10/2025 Lire →

Genomic and Clinical Predictors of Conversion in Initially Unresectable Colorectal Cancer Liver Metastases.

BACKGROUND: Colorectal cancer liver metastases (CRLM) present significant treatment challenges, requiring multimodal conversion therapies. Identifying factors that influence treatment outcomes is cruc…

Thérapies de Conversion

Zuo, D., Wang, L., Jin, K., Zhang, Y., Wang, Y., Sun, Y., & Tang, J. (2025). Genomic and Clinical Predictors of Conversion in Initially Unresectable Colorectal Cancer Liver Metastases.. Ann Surg Oncol, 32(10), 7173-7182. https://doi.org/10.1245/s10434-025-17809-5

01/10/2025 Lire →

CRABP2 promotes peritoneal metastasis in CRC through TGF-β/Smad-mediated EMT signaling and invadopodia formation.

Peritoneal metastasis (PM) in colorectal cancer (CRC) is typically associated with a lower likelihood of successful conversion therapy and a poorer prognosis compared to metastases at other sites. Inv…

Thérapies de Conversion

Hao, W., Dong, X., Wang, Z., Wen, T., Liu, L., Gu, T., & Ma, H. (2025). CRABP2 promotes peritoneal metastasis in CRC through TGF-β/Smad-mediated EMT signaling and invadopodia formation.. Cell Signal, 134, 111927. https://doi.org/10.1016/j.cellsig.2025.111927

01/10/2025 Lire →

Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study.

BACKGROUND: The conversion therapy for advanced hepatocellular carcinoma (HCC) shows promise with a triple therapy approach that combines interventional therapy, immune checkpoint inhibitors, and mole…

Thérapies de Conversion

Pan, Z., Liu, D., Cao, J., Fu, L., Zhang, X., Zhu, X., Pan, Y., Liu, J., Han, C., Jin, R., Shen, S., Zhang, X., Liu, H., Yang, X., Hu, K., Shi, X., Wang, D., Zhao, Y., Zhong, J., … China, L. i. v. e. r. . C. a. n. c. e. r. . S. t. u. d. y. . G. r. o. u. p. . Y. o. u. n. g. . I. n. v. e. s. t. i. g. a. t. o. r. s. . (. C. L. E. A. P. ). (2025). Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study.. Liver Cancer, 14(5), 601-619. https://doi.org/10.1159/000545545

01/10/2025 Lire →

The immune-reinforcements of Lenvatinib plus anti-PD-1 and their rationale to unite with TACE for unresectable hepatocellular carcinoma treatment.

BACKGROUND: Despite encouraging clinical benefits have gained by anti-PD-1 and Lenvatinib combination, in-depth characterizations about the mechanisms of action remain poorly characterized. Furthermor…

Thérapies de Conversion

Jiang, J., Zhang, H., Ou, Y., Lai, J., Huang, Y., Cai, W., Li, C., Zhang, L., & Fu, Y. (2025). The immune-reinforcements of Lenvatinib plus anti-PD-1 and their rationale to unite with TACE for unresectable hepatocellular carcinoma treatment.. Immunol Lett, 275, 107003. https://doi.org/10.1016/j.imlet.2025.107003

01/10/2025 Lire →

Glial Cell Reprogramming in Ischemic Stroke: A Review of Recent Advancements and Translational Challenges.

Ischemic stroke, the second leading cause of death worldwide and the leading cause of long-term disabilities, presents a significant global health challenge, particularly in aging populations where th…

Thérapies de Conversion

Greșiță, A., Hermann, D. M., Boboc, I. K. S., Doeppner, T. R., Petcu, E., Semida, G. F., & Popa-Wagner, A. (2025). Glial Cell Reprogramming in Ischemic Stroke: A Review of Recent Advancements and Translational Challenges.. Transl Stroke Res, 16(5), 1811-1835. https://doi.org/10.1007/s12975-025-01331-7

01/10/2025 Lire →

Direct conversion of ustekinumab therapy is more beneficial than infliximab-optimized therapy in patients with Crohn's disease who develop secondary loss of response to infliximab.

BACKGROUND: For patients with Crohn's disease (CD) who develop secondary loss of response (SLR) to infliximab (IFX), it remains unclear whether IFX optimization or direct conversion to ustekinumab (US…

Thérapies de Conversion

Li, L., Xu, X., Wang, J., Xie, L., & Niu, X. (2025). Direct conversion of ustekinumab therapy is more beneficial than infliximab-optimized therapy in patients with Crohn's disease who develop secondary loss of response to infliximab.. BMC Gastroenterol, 25(1), 685. https://doi.org/10.1186/s12876-025-04319-7

29/09/2025 Lire →

Decision-Making Biomarkers Guiding Therapeutic Strategies in Hepatocellular Carcinoma: From Prediction to Personalized Care.

Hepatocellular carcinoma (HCC) management has evolved remarkably with the advent of diverse therapeutic options, particularly systemic and surgical treatments. Combination immunotherapy has redefined …

Thérapies de Conversion

Liu, D., & Imai, N. (2025). Decision-Making Biomarkers Guiding Therapeutic Strategies in Hepatocellular Carcinoma: From Prediction to Personalized Care.. Cancers (Basel), 17(19). https://doi.org/10.3390/cancers17193105

24/09/2025 Lire →

Radiotherapy enhances triple therapy for conversion and survival in patients with unresectable hepatocellular carcinoma with portal vein tumor thrombus.

Triple therapy (TT), consisting of transarterial chemoembolization, immune checkpoint inhibitors, and tyrosine kinase inhibitors, is recommended as a conversion therapy for patients with unresectable …

Thérapies de Conversion

Zhou, Y., Yao, M., Wen, T., & Li, C. (2025). Radiotherapy enhances triple therapy for conversion and survival in patients with unresectable hepatocellular carcinoma with portal vein tumor thrombus.. Biosci Trends, 19(4), 468-478. https://doi.org/10.5582/bst.2025.01170

17/09/2025 Lire →